A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment
Latest Information Update: 23 May 2025
At a glance
- Drugs Bromelains (Primary) ; Bromelains (Primary)
- Indications Burns
- Focus Registrational; Therapeutic Use
- Acronyms CIDS
- Sponsors MediWound
Most Recent Events
- 01 May 2025 Results assessing the safety and efficacy of bromelain-based debridement in children with deep burns as compared to the standard of care (SOC) eschar removal techniques, published in the Burns.
- 24 Feb 2025 According to a MediWound media release, The publication of this study presents findings that supported the label expansion of NexoBrid for pediatric patients in the E.U. (2023) and U.S. (2024).
- 24 Feb 2025 According to a MediWound media release, the company announced the publication of its Phase III Children Innovative Debridement Study (CIDS) in Burns, the peer-reviewed Journal of the International Society for Burn Injuries (ISBI).